Navigation Links
Medisafe 1 Technologies Corp Notify Shareholders on FINRA's Approval of the 5-1 Stock Dividend
Date:9/16/2010

Medisafe 1 Technologies Corp Notify Shareholders on FINRA's Approval of the 5-1 Stock... -- JERUSALEM, September 16, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Biotechnology, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, Dividends, Stock Split Click to view news release full screen  

Medisafe 1 Technologies Corp Notify Shareholders on FINRA's Approval of the 5-1 Stock Dividend

   

Holders of Record Date set at the Close of September 17 2010 and Payable Date on September 20 2010

JERUSALEM, September 16, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, will be issuing and completing a forward stock split of 5-1 in the form of a stock dividend on its common shares.

The stock dividend has been approved by FINRA and will be paid on September 20 2010 to the shareholders of record on September 17 2010.When the stock dividend becomes effective, each shareholder who holds one restricted stock will receive an additional 4 shares of restricted stock and each shareholder who holds one unrestricted stock will receive an additional 4 shares of unrestricted stock. Medisafe 1 Technologies currently has 10,000,000 shares outstanding. The forward stock split in the form of the issuance of the dividend will increase the total shares outstanding to 50,000,000. Medisafe 1 expects the Board's decision will improve liquidity and trading volume in the Company's stock.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact: JACOB ELHADAD CEO +972-524440000 JACOB.ELHADAD10@GMAIL.COM
'/>"/>

SOURCE Medisafe 1 Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company
2. Medisafe 1 Technologies Finalises Contract to Develop Prototype of the Worlds First Ever Medicinal Syringe-Locking Device
3. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
6. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
7. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
8. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
9. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. Senesco Technologies Initiates Preclinical Studies for Cancer Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
Breaking Medicine News(10 mins):